Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Ambu Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

AmbuDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -21.2% zurückgegangen, während in der Branche Medical Equipment die Gewinne wachsen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 11.7% pro Jahr. Ambu Die Eigenkapitalrendite des Unternehmens beträgt 6.5%, und die Nettomargen liegen bei 7.2%.

Wichtige Informationen

-21.2%

Wachstumsrate der Gewinne

-23.1%

EPS-Wachstumsrate

Medical Equipment Wachstum der Industrie	-1.7%
Wachstumsrate der Einnahmen	11.7%
Eigenkapitalrendite	6.5%
Netto-Marge	7.2%
Nächste Ertragsaktualisierung	30 Aug 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity

Apr 06

Returns On Capital Signal Tricky Times Ahead For Ambu (CPH:AMBU B)

Mar 14

Results: Ambu A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 01

Aufschlüsselung der Einnahmen und Ausgaben

Wie Ambu Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

CPSE:AMBU B Einnahmen, Ausgaben und Erträge (DKK Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	5,075	367	2,119	312
31 Dec 23	4,897	238	2,130	300
30 Sep 23	4,775	168	2,116	295
30 Jun 23	4,679	-42	2,151	293
31 Mar 23	4,612	-65	2,160	290
31 Dec 22	4,545	95	2,146	286
30 Sep 22	4,444	93	2,151	281
30 Jun 22	4,307	222	2,113	274
31 Mar 22	4,152	256	2,065	255
31 Dec 21	4,031	176	2,001	242
30 Sep 21	4,013	247	1,938	225
30 Jun 21	3,858	251	1,861	210
31 Mar 21	3,832	281	1,810	198
31 Dec 20	3,820	290	1,760	174
30 Sep 20	3,567	241	1,627	157
30 Jun 20	3,302	146	1,462	126
31 Mar 20	3,128	270	1,301	111
31 Dec 19	2,924	296	1,134	106
30 Sep 19	2,820	317	1,054	103
30 Jun 19	2,943	515	1,000	103
31 Mar 19	2,843	411	962	111
31 Dec 18	2,709	372	920	114
30 Sep 18	2,606	337	872	111
30 Jun 18	2,506	318	848	104
31 Mar 18	2,434	288	824	90
31 Dec 17	2,396	281	804	82
30 Sep 17	2,355	301	790	76
30 Jun 17	2,299	306	747	71
31 Mar 17	2,215	299	726	69
31 Dec 16	2,134	267	711	68
30 Sep 16	2,084	250	700	66
30 Jun 16	2,047	224	715	65
31 Mar 16	2,012	169	700	61
31 Dec 15	1,963	175	692	58
30 Sep 15	1,889	152	665	55
30 Jun 15	1,795	171	616	53
31 Mar 15	1,710	184	597	50
31 Dec 14	1,630	156	564	45
30 Sep 14	1,584	151	556	44
30 Jun 14	1,543	94	548	42
31 Mar 14	1,524	67	543	40
31 Dec 13	1,456	40	524	39
30 Sep 13	1,383	48	488	33
30 Jun 13	1,265	56	461	27

Qualität der Erträge: AMBU B hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: AMBU B in der Vergangenheit profitabel geworden.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: AMBU BDie Erträge des Unternehmens sind in den letzten 5 Jahren um 21.2% pro Jahr zurückgegangen.

Beschleunigtes Wachstum: AMBU B ist im letzten Jahr profitabel geworden, so dass die Wachstumsrate der Gewinne nur schwer mit dem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: AMBU B ist im letzten Jahr profitabel geworden, so dass es schwierig ist, das Gewinnwachstum des letzten Jahres mit dem der Branche Medical Equipment (4.9%) zu vergleichen.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: AMBU BDie Eigenkapitalrendite des Unternehmens (6.5%) wird als niedrig angesehen.

Ambu Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2024 earnings: EPS misses analyst expectations

First quarter 2024 earnings released

Ambu A/S to Report Q2, 2024 Results on May 14, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings: Revenues in line with analyst expectations

First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)

Recent updates

Consensus EPS estimates increase by 14%

Second quarter 2024 earnings: EPS misses analyst expectations

Ambu A/S' (CPH:AMBU B) Subdued P/S Might Signal An Opportunity

Returns On Capital Signal Tricky Times Ahead For Ambu (CPH:AMBU B)

Results: Ambu A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings released

Ambu A/S Maintains Earnings Guidance for the Full-Year 2023/24

Price target increased by 10% to kr.101

Price target increased by 7.2% to kr.91.83

A Piece Of The Puzzle Missing From Ambu A/S' (CPH:AMBU B) Share Price

Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors

Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors

Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24

Price target decreased by 9.0% to kr.87.00

Is Ambu A/S (CPH:AMBU B) Trading At A 42% Discount?

Ambu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024

Ambu A/S Announces Chief Financial Officer Changes

Ambu A/S to Report Q2, 2024 Results on May 14, 2024

Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends

Ambu A/S Narrows Earnings Guidance for the Full-Year 2022/23

Third quarter 2023 earnings released

Does Ambu (CPH:AMBU B) Have A Healthy Balance Sheet?

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

Does This Valuation Of Ambu A/S (CPH:AMBU B) Imply Investors Are Overpaying?

Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023

New minor risk - Share price stability

Returns On Capital At Ambu (CPH:AMBU B) Paint A Concerning Picture

Ambu (CPH:AMBU B) Has A Somewhat Strained Balance Sheet

Second quarter 2023 earnings: Revenues in line with analyst expectations

Price target decreased by 8.7% to kr.95.50

Returns On Capital At Ambu (CPH:AMBU B) Paint A Concerning Picture

Consensus EPS estimates fall by 15%

Consensus EPS estimates increase by 14%

Price target increased by 16% to kr.96.80

First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

We Think Ambu (CPH:AMBU B) Is Taking Some Risk With Its Debt

Ambu (CPH:AMBU B) Will Be Hoping To Turn Its Returns On Capital Around

High number of new directors

Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Ambu A/S to Report Q3, 2023 Results on Aug 31, 2023

Is Ambu A/S (CPH:AMBU B) Trading At A 30% Discount?

Ambu A/S(CPSE:AMBU B) dropped from FTSE All-World Index (USD)

Ambu (CPH:AMBU B) Will Want To Turn Around Its Return Trends

Now 20% undervalued after recent price drop

Price target decreased to kr.76.50

Third quarter 2022 earnings: Revenues in line with analyst expectations

Ambu A/S Reaffirms Earnings Guidance for the Full-Year 2021/2022

We Think Ambu (CPH:AMBU B) Is Taking Some Risk With Its Debt

Consensus forecasts updated

Ambu A/S Revises Earnings Guidance for the Full-Year 2021/2022

Ambu Announces FDA Clearance of Fifth-Generation Single-Use Bronchoscope

Investor sentiment deteriorated over the past week

Ambu (CPH:AMBU B) Could Be Struggling To Allocate Capital

Price target decreased to kr.94.25

Ambu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22

These 4 Measures Indicate That Ambu (CPH:AMBU B) Is Using Debt Extensively

Consensus forecasts updated

Second quarter 2022 earnings: Revenues in line with analyst expectations

Price target decreased to kr.137

Less than half of directors are independent

First quarter 2022 earnings: EPS misses analyst expectations

Ambu A/S Revises Revenue Guidance for the Fiscal 2022

Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display Unit

Does Ambu (CPH:AMBU B) Have A Healthy Balance Sheet?

Are Investors Undervaluing Ambu A/S (CPH:AMBU B) By 27%?

Upcoming dividend of kr.0.29 per share